TY - JOUR
T1 - Romiplostim for treatment of thrombocytopenia in dogs
T2 - A retrospective assessment and clinical outcomes
AU - Ryu, Min Ok
AU - Kim, Jin Kyung
AU - An, Ju Hyun
AU - Seo, Kyoung Won
AU - Oh, Ye In
AU - Youn, Hwa Young
N1 - Publisher Copyright:
© 2024 The Author(s). Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.
PY - 2024/7/1
Y1 - 2024/7/1
N2 - Background: Romiplostim, a thrombopoietin analog, is commonly used to treat immune-mediated thrombocytopenia (ITP) in humans, but its use in dogs remains limited. Objectives: Evaluate the effects and adverse events of romiplostim administration in dogs with thrombocytopenia caused by various underlying diseases. Animals: Forty-two client-owned dogs with naturally occurring thrombocytopenia at 2 referral animal hospitals. Methods: Retrospective, multi-institutional analysis to evaluate the outcomes of romiplostim treatment in dogs. Results: Among the dogs treated with romiplostim, 27 experienced an increase in platelet count and 26 maintained a platelet count within the reference range. Platelet count improvement was observed in various conditions: primary ITP (90%, n = 18/20), pancytopenia of unknown etiology (42.9%, n = 3/7), chemotherapy-induced thrombocytopenia (50%, n = 3/6), babesiosis (100%, n = 1/1), radiotherapy-induced thrombocytopenia (0%, n = 0/1), and disseminated intravascular coagulopathy (33.3%, n = 2/6). The median time for platelet recovery (>50 000/μL) after romiplostim administration was 4 days, and the median time for platelet count normalization was 7 days. Median hospitalization time for the improvement group (I) was 5 days. The survival-to-discharge rates were 85%, 40%, and 28.6% for dogs with primary ITP, secondary thrombocytopenia, and thrombocytopenia of unknown etiology, respectively. Conclusions and Clinical Importance: Romiplostim is a well-tolerated and promising treatment for primary ITP in dogs, suggesting its potential as a valuable therapeutic option for dogs with thrombocytopenia caused by various underlying conditions. These findings emphasize the need for further research to optimize romiplostim dosing and understand its role in treating secondary thrombocytopenia and pancytopenia of unknown etiology.
AB - Background: Romiplostim, a thrombopoietin analog, is commonly used to treat immune-mediated thrombocytopenia (ITP) in humans, but its use in dogs remains limited. Objectives: Evaluate the effects and adverse events of romiplostim administration in dogs with thrombocytopenia caused by various underlying diseases. Animals: Forty-two client-owned dogs with naturally occurring thrombocytopenia at 2 referral animal hospitals. Methods: Retrospective, multi-institutional analysis to evaluate the outcomes of romiplostim treatment in dogs. Results: Among the dogs treated with romiplostim, 27 experienced an increase in platelet count and 26 maintained a platelet count within the reference range. Platelet count improvement was observed in various conditions: primary ITP (90%, n = 18/20), pancytopenia of unknown etiology (42.9%, n = 3/7), chemotherapy-induced thrombocytopenia (50%, n = 3/6), babesiosis (100%, n = 1/1), radiotherapy-induced thrombocytopenia (0%, n = 0/1), and disseminated intravascular coagulopathy (33.3%, n = 2/6). The median time for platelet recovery (>50 000/μL) after romiplostim administration was 4 days, and the median time for platelet count normalization was 7 days. Median hospitalization time for the improvement group (I) was 5 days. The survival-to-discharge rates were 85%, 40%, and 28.6% for dogs with primary ITP, secondary thrombocytopenia, and thrombocytopenia of unknown etiology, respectively. Conclusions and Clinical Importance: Romiplostim is a well-tolerated and promising treatment for primary ITP in dogs, suggesting its potential as a valuable therapeutic option for dogs with thrombocytopenia caused by various underlying conditions. These findings emphasize the need for further research to optimize romiplostim dosing and understand its role in treating secondary thrombocytopenia and pancytopenia of unknown etiology.
KW - canine
KW - immune-mediated
KW - pancytopenia
KW - thrombopoietin
UR - http://www.scopus.com/inward/record.url?scp=85196662800&partnerID=8YFLogxK
U2 - 10.1111/jvim.17131
DO - 10.1111/jvim.17131
M3 - Article
C2 - 39023218
AN - SCOPUS:85196662800
SN - 0891-6640
VL - 38
SP - 2158
EP - 2164
JO - Journal of Veterinary Internal Medicine
JF - Journal of Veterinary Internal Medicine
IS - 4
ER -